 |
172 Diseases |  |
135 Trials |
|
135 Trials |  |
7089 News |  |
| «12...4344454647484950515253...7475» |
- Lucentis (ranibizumab) / Roche, Novartis, conbercept (KH902) / Chengdu Kanghong
Comparison of the effect of intravitreal conbercept and ranibizumab on aqueous humor cytokines in macular edema secondary to central retinal vein occlusion (Amphitheatre Havane (Level 3)) - Sep 26, 2019 - Abstract #EURETINA2019EURETINA_1704;
In eyes with macular edema secondary to CRVO, both IVC and IVR achieved similar improvement in clinical parameters and similar reductions in aqueous humor levels of angiogenic and inflammatory cytokines.
- Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Comparison of aflibercept versus ranibizumab in patients with myopic choroidal neovascularization (Amphitheatre Havane (Level 3)) - Sep 26, 2019 - Abstract #EURETINA2019EURETINA_1695;
In eyes with macular edema secondary to CRVO, both IVC and IVR achieved similar improvement in clinical parameters and similar reductions in aqueous humor levels of angiogenic and inflammatory cytokines. Both Aflibercept and Ranibizumab provided a comparable improvement in visual acuity and reduction of retinal thickness in patients with myopic CNV.
- Lucentis (ranibizumab) / Roche, Novartis
Success rate of decision making to extend in the treat and extend ranibizumab regimen for neovascular age related macular degeneration (Arlequin) - Sep 26, 2019 - Abstract #EURETINA2019EURETINA_1646;
This study further supports the use of treat and extend regimen in the real world using OCT scan criteria mainly for determining lesion activity. In addition to patient level outcomes, we also investigated the types of decision made at each visit for all patients.
- Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Comparison of one-year outcome of photodynamic therapy in combination with intravitreal aflibercept or ranibizumab for polypoidal choroidal vasculopathy (Room 241 (Level 2)) - Sep 26, 2019 - Abstract #EURETINA2019EURETINA_1632;
Combined IVR and PDT can only reduce macular thickness but not increase visual acuity. Comparable macular thickness decrease, dry macula rate, polyp regression rate, and PDT treatment number were found between two groups.
- Lucentis (ranibizumab) / Roche, Novartis, ceftazidime / Generic Mfg.
Real-world data on endophthalmitis after intravitreal anti-vascular endothelial growth factor injections with or without topical antibiotic prophylaxis (Room 241 (Level 2)) - Sep 26, 2019 - Abstract #EURETINA2019EURETINA_1631;
Topical antibiotic prophylaxis was not associated with decreased rates of endophthalmitis. Gram-positive organisms, specifically coagulase negative Staphylococcus and Streptococcus pneumoniae were the main causative organisms.
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Swept-source optical coherence tomography (ssOCT) imaging in vitreoretinal interface disorders (VRID) and their role in intravitreal treatment response in wet age-related macular degeneration (AMD) (Arlequin) - Sep 26, 2019 - Abstract #EURETINA2019EURETINA_1605;
We present a large sample that can lead to future investigations to reinforce our results. It seems vitreomacular abnormalities are not an adverse prognosis factor in wet AMD, as it was commonly thought with previous publications.
- Lucentis (ranibizumab) / Roche, Novartis
Polyp evolution over 24 months among patients with polypoidal choroidal vasculopathy (Arlequin) - Sep 26, 2019 - Abstract #EURETINA2019EURETINA_1603;
The status of polyps in PCV vary during the course of treatment, with some polyps originally present at baseline persisting, while in some eyes new polyps develop. Most new polyps developed from 12 months.
- Lucentis (ranibizumab) / Roche, Novartis
Drug utilization and associated visual acuity in patients treated with anti-VEGFs for neovascular age-related macular degeneration (nAMD) in the UK (Arlequin) - Sep 26, 2019 - Abstract #EURETINA2019EURETINA_1594;
The average number of injections during both years of treatment was substantially lower than the ≥8 (year 1) and ≥6 (year 2) injections reported in TREX-AMD, LUCAS, TREND, RIVAL and ATLAS randomised clinical trials. The absence of improvement in mean VA change from baseline at the end of the second year may be exacerbated by under-treatment that is also associated with treatment intervals of >12 weeks.
- Lucentis (ranibizumab) / Roche, Novartis
Bringing clinical trials results to real life in nAMD. Results of an advanced intravitreal treatment setting in a public hospital in Spain (Arlequin) - Sep 26, 2019 - Abstract #EURETINA2019EURETINA_1592;
The results were similar to those observed in our real clinical practice. The treatment strategy T & E is one of the most used nowadays because it favors a better planning and organization of the treatment units, facilitating the review and treatment in one-stop clinic.
- Lucentis (ranibizumab) / Roche, Novartis
Anti-VEGF persistence and switching in nAMD: real world analysis from a Canadian claims database (Arlequin) - Sep 26, 2019 - Abstract #EURETINA2019EURETINA_1591;
This study sought to characterize dosing frequency for persistent nAMD patients and evaluate switching from one licensed anti-VEGF agent to another. Persistency was defined as consecutive claims less than 90 days apart.
- Lucentis (ranibizumab) / Roche, Novartis
Influence of mitochondrial haplogroups in response to ranibizumab therapy in neovascular age-related macular degeneration. (Arlequin) - Sep 26, 2019 - Abstract #EURETINA2019EURETINA_1590;
mtDNA genetic background showed different response to intravitreal ranibizumab therapy at 12 month. It could be a potencial biomarker to predict the response to intravitreal ranibizumab therapy in nAMD patients.
- Lucentis (ranibizumab) / Roche, Novartis
Anti-vegf therapy with/without initial steroid therapy for macular edema in branch retinal vein occlusion (Arlequin) - Sep 26, 2019 - Abstract #EURETINA2019EURETINA_1549;
BRVO patients with macular edema (42 eyes) received intravitreal ranibizumab injection (IRI) alone [IRI group: 25 eyes] or IRI following subtenon triamcinolone (STTA) [combined group: 17 eyes]... These findings suggest that combined therapy with STTA followed by IRI may reduce the expression of inflammatory factors and suppress the recurrence of macular edema in BRVO patients.
- Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Comparing real-world outcomes of intravitreal anti-VEGF therapy for macular oedema secondary to central retinal vein occlusion between a Swiss and UK teaching hospital (Amphitheatre Havane (Level 3)) - Sep 26, 2019 - Abstract #EURETINA2019EURETINA_1530;
Both centres achieved significant visual gains and anatomical improvements but these were not of the magnitude of phase III RCTs. An explanation for this may be the different baseline characteristics and injection numbers between real world and RCT settings.
- Lucentis (ranibizumab) / Roche, Novartis
Artificial intelligence algorithm that predicts diabetic retinopathy (DR) response to anti-VEGF treatment in patients via deep learning (DL) (Amphitheatre Havane (Level 3)) - Sep 26, 2019 - Abstract #EURETINA2019EURETINA_1526;
Our work demonstrated the feasibility of a deep learning algorithm to predict DR response to anti-VEGF therapy from the baseline color fundus photographs at an individual patient level. CFPs from anti-VEGF treated DR patients without DME are needed for further validation and to translate the current pilot algorithm to the real world setting.
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Anti-VEGF in retinal vein occlusions: real data for long term outcomes (Amphitheatre Havane (Level 3)) - Sep 26, 2019 - Abstract #EURETINA2019EURETINA_1524;
Patients data were registered on Medisoft software. Patients affected by RVO who require consistent long-term anti-VEGF therapy are likely able to maintain or improve their vision.
- faricimab (RG7716) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Anatomical and durability outcomes from the BOULEVARD phase 2 trial of faricimab for DME (Amphitheatre Havane (Level 3)) - Sep 26, 2019 - Abstract #EURETINA2019EURETINA_1523;
P2, P3
Additional analyses of phase 2 data highlight anatomical benefits and potential for extended durability with faricimab in both patient populations compared with anti-VEGF monotherapy. Study design details will be presented for the ongoing phase 3 YOSEMITE (NCT03622580) and RHINE (NCT03622593) trials assessing extended interval dosing of faricimab for DME.
- Avastin (bevacizumab) / Roche, Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Aflibercept in macular oedema secondary to retinal vein occlusion refractory to previous bevacizumab or ranibizumab: 24 week outcomes (Amphitheatre Havane (Level 3)) - Sep 26, 2019 - Abstract #EURETINA2019EURETINA_1521;
Switching anti-VEGF therapy in persistent macular oedema was associated with anatomical improvement in the majority of eyes and ⩾3 lines of vision improvement in 77% of eyes. This effect is more prominent in eyes with a greater CMT prior to the switch.
- Real-time data on the clinical outcomes of fluocinolone acetonide (Iluvien) implant use in chronic diabetic macular oedema in pseudophakic patients (Arlequin (Level 3)) - Sep 26, 2019 - Abstract #EURETINA2019EURETINA_1470;
There was also a statistically significant reduction in the number of post-Iluvien interventions required (p value = 0.0102). The treatment proved to be safe, with no change in IOP or post-treatment complications noted.
- Lucentis (ranibizumab) / Roche, Novartis
Automated detection and quantification of spectral domain optical coherence tomography hyper-reflective foci in eyes with retinal vein occlusion (Arlequin (Level 3)) - Sep 26, 2019 - Abstract #EURETINA2019EURETINA_1463;
At baseline, BRVO/CRVO differences in HRF density, SRF volume, IRC volume, and RT were statistically significant. Apparently, the resolution of HRF under anti-VEGF therapy followed different slopes: while in CRVO HRF density decline was measurable after the first treatment and continuously ongoing in the same direction, in BRVO the density initially increased until month 3 and decreased from then on.
- Lucentis (ranibizumab) / Roche, Novartis
Analysis of retinal layer thickness and choroidal thickness in diabetic macular oedema treated with ranibizumab or aflibercept (Arlequin (Level 3)) - Sep 26, 2019 - Abstract #EURETINA2019EURETINA_1461;
Over a 3-month period, the use of intravitreal anti-VEGF agents was associated with significant thinning of the choroid, CMT and RNFL in patients with DME. GCC thickness increased after injections.
- Lucentis (ranibizumab) / Roche, Novartis
Key confounders for translating results from non-interventional trials (NIS) to those observed in randomized controlled trials (RCTs): applying predictive analytics in neovascular age-related macular degeneration (nAMD) (Room 241 (Level 2)) - Sep 26, 2019 - Abstract #EURETINA2019EURETINA_1452;
The association of age and baseline VA with clinical outcomes is supported by existing literature. The European clinical guidelines for the management of nAMD (EURETINA) highlights the importance of optical coherence tomography (OCT) biomarkers in VA prognosis.
- Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Intravitreal ranibizumab versus aflibercept following treat and extend protocol for neovascular age-related macular degeneration (2 years follow up) (Room 241 (Level 2)) - Sep 26, 2019 - Abstract #EURETINA2019EURETINA_1449;
Statistically significant differences regarding BCVA, central macular thickness and number of injections were not found between aflibercept and ranibizumab at 24 months. On the other hand, there was higher tendency of recurrence rates, statistically non-significant, in aflibercept group compared to ranibizumab group after following identical treat and extend protocol.
- Lucentis (ranibizumab) / Roche, Novartis
Key confounders for translating results from non-interventional trials (NIS) to those observed in randomized controlled trials (RCTs): applying predictive analytics in neovascular age-related macular degeneration (nAMD) (Room 241) - Sep 26, 2019 - Abstract #EURETINA2019EURETINA_1425;
The association of age and baseline VA with clinical outcomes is supported by existing literature. The European clinical guidelines for the management of nAMD (EURETINA) highlights the importance of optical coherence tomography (OCT) biomarkers in VA prognosis.
- Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Intravitreal ranibizumab versus aflibercept following treat and extend protocol for neovascular age-related macular degeneration (2 years follow up) (Room 241) - Sep 26, 2019 - Abstract #EURETINA2019EURETINA_1422;
Statistically significant differences regarding BCVA, central macular thickness and number of injections were not found between aflibercept and ranibizumab at 24 months. On the other hand, there was higher tendency of recurrence rates, statistically non-significant, in aflibercept group compared to ranibizumab group after following identical treat and extend protocol.
- Lucentis (ranibizumab) / Roche, Novartis
Evaluation of vitreoretinal surgery results in patients with epiretinal membrane associated with diabetic macular edema which is resistant to intravitreal treatment () - Sep 26, 2019 - Abstract #EURETINA2019EURETINA_1413;
Visual acuity improves and central foveal thickness decreases after surgery. In order to determine the effectiveness of peroperative ILM peeling, comparative studies with larger series are needed.
- Lucentis (ranibizumab) / Roche, Novartis
Successful management of retinopathy of prematurity with acute progression after anti-VEGF intravitreal injection () - Sep 26, 2019 - Abstract #EURETINA2019EURETINA_1412;
Early detection and timely intervention can obtain good anatomical structure and visual function. Vitrectomy combined with laser photocoagulation may be the best choice to block the progression of ROP if progresses to TDR.
- Lucentis (ranibizumab) / Roche, Novartis, conbercept (KH902) / Chengdu Kanghong
Intravitreal conbercept versus ranibizumab as a preoperative adjunct to vitrectomy for preventing recurrent vitreous hemorrhage in proliferative diabetic retinopathy () - Sep 26, 2019 - Abstract #EURETINA2019EURETINA_1353;
IVC and IVR as a preoperative adjunct to vitrectomy could prevent recurrent VH in patients with PDR effectively, and relatively safe. However, a high-quality, multicenter, large sample, long-term RCT is warranted to be further investigated.
- Lucentis (ranibizumab) / Roche, Novartis
Vitreous syneresis after intravitreal injection of ranibizumab in treatment of ROP () - Sep 26, 2019 - Abstract #EURETINA2019EURETINA_1281;
Development of membraneous formation in the AP-ROP-group may due to incompleted involution of the primary vitreus in very small infants. Syneresis of the vitreous in both groups may due to unsuffecient development of the secondary vitreous in prematüre/immatüre infants with immatüre retinal development and unsufficient Müller cells, which are mainly involved in collagenfiber synthesis of secondary vitreus.
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Evaluation of vitrectomy with planned foveal detachment as surgical treatment for refractory diabetic macular edema with or without vitreo-macular interface abnormality () - Sep 26, 2019 - Abstract #EURETINA2019EURETINA_1277;
Reduction of CMT was shown to occur more effectively in eyes were vitrectomy was not attempted before this study. Moreover, cases with ERM resistant to pharmacotherapy responded well to this technique.
- Lucentis (ranibizumab) / Roche, Novartis
Stereopsis following intravitreal ranibizumab for branch retinal vein occlusion () - Sep 26, 2019 - Abstract #EURETINA2019EURETINA_1272;
IVR for BRVO improved early stereopsis, albeit not to a normal level. Presence of SRD and visual acuity were found to be predictors of post-treatment stereopsis in patients with BRVO.
- Lucentis (ranibizumab) / Roche, Novartis
Outcomes from the treatment of naïve macular edema after branch retinal vein occlusion with ranibizumab. () - Sep 26, 2019 - Abstract #EURETINA2019EURETINA_1267;
Presence of SRD and visual acuity were found to be predictors of post-treatment stereopsis in patients with BRVO. The treatment of naïve macular edema after BVRO with ranibizumab is safe and effective in improving visual acuity and CMT at one year follow-up.
- Azopt (brinzolamide ophthalmic suspension 1%) / Novartis, Entyvio (vedolizumab) / Takeda, Lucentis (ranibizumab) / Roche, Novartis
Ischaemic central retinal vein occlusion combined with cilioretinal artery occlusion in a 40-year-old patient receiving Vedolizumab for ulcerative colitis: a case report. () - Sep 26, 2019 - Abstract #EURETINA2019EURETINA_1266;
Vedolizumab has received FDA and European Commission approval for use in the treatment of moderate to severe active ulcerative colitis and Crohn's disease. This medicinal product is subject to additional monitoring in order to allow quick identification of new safety information.There is one case of central retinal vein occlusion and one case of optic neuropathy reported in the literature with the use of Vedolizumab.Our case of ischaemic central retinal vein occlusion associated with cilioretinal artery occlusion in a young patient receiving Vedolizumab for ulcerative colitis may represent an additional ophthalmological involvement which was observed soon after the initiation of this biological agent.
- Lucentis (ranibizumab) / Roche, Novartis
Epidemiological study of retinopathy of prematurity in dalian and short-term efficacy of anti-vegf therapy () - Sep 26, 2019 - Abstract #EURETINA2019EURETINA_1262;
The birth gestational age, birth weight, oxygen intake and pregnancy history are independence dangerous factors of ROP, and the birth gestational age and birth weight are negatively correlated with ROP. The oxygen inhalation time is positively related with ROP.
- Lucentis (ranibizumab) / Roche, Novartis, conbercept (KH902) / Chengdu Kanghong
Comparison of short-term efficacy between conbercept and ranibizumab for treatment of myopic choroidal neovascularization () - Sep 26, 2019 - Abstract #EURETINA2019EURETINA_1260;
The study showed functional and anatomical improvement after treatment of conbercept and ranibizumab for myopic CNV during a 6-month follow-up period, but conbercept may be more effective than ranibizumab in promoting CFT reduction and CNV lesion reduction at 1 month after intravitreal injection and it may have a fewer injections than ranibizumab. A larger, longer period and randomized double shamed study is required to determine the efficacy of these two drugs.
- Lucentis (ranibizumab) / Roche, Novartis
When the patient hides the answer: a case report of a radiation retinopathy () - Sep 26, 2019 - Abstract #EURETINA2019EURETINA_1259;
Radiation retinopathy can be a sight-threatening condition occurring after retinal exposure to irradiation treatment. It presents a clinical picture similar to changes seen in other retinopathies such as diabetic retinopathy, obstructions of retinal veins and retinal telangiectasia, so a high clinical suspicion based on a detailed medical past history is essential for diagnosis.
- Lucentis (ranibizumab) / Roche, Novartis
Ultrasound doppler and OCT-angiography in assessment of ocular blood flow in diabetic macular edema () - Sep 26, 2019 - Abstract #EURETINA2019EURETINA_1247;
Thus, using ultrasound Doppler and OCT-angiographyfor assessment of OBF we registered no negative effect of antiangiogenic therapy on microcirculation of the retina and retrobulbar circulation. During the follow-up period (1 month), there was an insignificant improvement in hemodynamics in the CRA, normalization of blood flow in OA, and absence of significant changes in the microvascular network and FAZ area, which may indicate improvement of hemodynamic parameters with the reabsorption of macular edema.
- Lucentis (ranibizumab) / Roche, Novartis
Intravitreal ranibizumab and dexamethasone implant injections as primary treatment of diabetic macular edema: simultaneously double protocol () - Sep 26, 2019 - Abstract #EURETINA2019EURETINA_1245;
During the follow-up period (1 month), there was an insignificant improvement in hemodynamics in the CRA, normalization of blood flow in OA, and absence of significant changes in the microvascular network and FAZ area, which may indicate improvement of hemodynamic parameters with the reabsorption of macular edema. The simultaneous addition of DEX implant at any time during the three-monthly loading doses of ranibizumab in patients with DME significantly improved the visual outcomes and revealed superior anatomic outcomes than those with the ranibizumab monotherapy.
- Lucentis (ranibizumab) / Roche, Novartis
Hypoestrogenemia in the pathogenesis of myopic chorioretinal neovapscularization () - Sep 26, 2019 - Abstract #EURETINA2019EURETINA_1235;
Estrogen reduces the level of inflammation in the vascular wall, stimulates vascular relaxation by stimulating and releasing nitric oxide, and acts directly on the smooth muscle of the vascular wall. The Results obtained in the works of Kobayashi K. showed the presence of estrogen receptors in the CNV in patients with myopia.
- Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Comparing Lucentis (Ranibizumab) and Eylea (Aflibercept) for macular oedema secondary to central retinal vein occlusion () - Sep 26, 2019 - Abstract #EURETINA2019EURETINA_1223;
Aflibercept significantly improved visual acuity over a 12-month period compared to ranibizumab. However, both ranibizumab and aflibercept demonstrate similar outcomes in central retinal thickness over a 12 month follow up period in patients with macular oedema secondary to central retinal vein occlusion.
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Long-term functional and anatomical outcomes following retinal vein occlusion (RVO) () - Sep 26, 2019 - Abstract #EURETINA2019EURETINA_1221;
Our Results indicate that most eyes maintained VA after 5 years and that 40% still had reading vision. Final BCVA did not correlate with the number of injections.
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Eale’s disease in patients of southeast Asian descent in India () - Sep 26, 2019 - Abstract #EURETINA2019EURETINA_1218;
Haemoglobin E which is very common in people of Southeast Asian origin in North-East India and many suffer from mild microcytic anemia. Which may contribute towards extensive disease.
- Lucentis (ranibizumab) / Roche, Novartis
Smoking as a risk factor for recurrent vitreous haemorrhage in patients with proliferative diabetic retinopathy () - Sep 26, 2019 - Abstract #EURETINA2019EURETINA_1217;
Eyes which had previously been treated with ranibizumab due to macular edema were also evaluated.Results : In total, 183 eyes [64%] with PDR had vitreous haemorrhage [VH], of which 68 [37%] underwent recurrent vitreous haemorrhage [RVH]... In our study, men with PDR who smoked, with longer duration of their diabetes, with anaemia and that had previously suffered from cardiovascular events, were more prone to suffer from RVH.
- Lucentis (ranibizumab) / Roche, Novartis
Dexamethasone implant for refractory macular edema in adult Coat’s disease () - Sep 26, 2019 - Abstract #EURETINA2019EURETINA_1213;
Satisfactory anatomical Results were observed with a dexamethasone implant 2 months after implantation and this result was not seen with numerous anti-VEGF injection, indicating that dexamethasone implant may be more potent to treat macular edema in Coats disease compared to anti-VEGF intravitreal injection. Further studies are necessary to confirm dexamethasone implant could a first line treatment for macula edema in adult onset Coats disease.
- Lucentis (ranibizumab) / Roche, Novartis
combination of intravitreal ranibizumab injection and laser for treatment of macular edema secondary to retinal artery macroaneurysm () - Sep 26, 2019 - Abstract #EURETINA2019EURETINA_1211;
Combining 3 intravitreal anti-VEGF injection with direct and indirect argon laser photocoagulation could be an ideal method of treating macular edema secondary to exudative type of retinal artery macroaneurysm. Longer follow up period is required to evaluate the efficacy of this protocol to maintain the visual acuity and to evaluate the incidence of recurrence and requirement for re-injection
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Diabetic macular oedema: real life results of intravitreal injection of anti-VEGF () - Sep 26, 2019 - Abstract #EURETINA2019EURETINA_1205;
Purpose: To study the long term outcomes in a large cohort of patients affected by Diabetic Macular Oedema (DMO) treated with bevacizumab, ranibizumab, and Aflibercept.Setting: Monocentric real world retrospective study./ The Western Eye HospitalMethods : Patients data were registered on Medisoft software. A slight increase in visual acuity was highlighted and we could affirm that anti-VEGF treatment represents a useful tool in DMO also in the long term without important local side effects.
- Ozurdex (dexamethasone intravitreal implant) / Allergan, Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Comparing the efficacy of intravitreal lucentis, eylea and ozurdex for patients with macular oedema following a retinal vein occlusion in a single centre () - Sep 26, 2019 - Abstract #EURETINA2019EURETINA_1202;
Our study suggested that 42% patients improved 2 or more lines at 12 months reducing to 38% at 24 months. IVT Eylea has shown to be more superior in terms of CMT improvement at 24 months.
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Anti-VEGF treatment in cases of Zone-1 aggressive retinopathy of prematurity () - Sep 26, 2019 - Abstract #EURETINA2019EURETINA_1188;
Intravitreal ranibizumab (0.25 mg/0.025 ml) or intravitreal bevacizumab (0.625 mg/0.025 ml) was injected under topical anesthesia. Anti-VEGF treatment is beneficial in zone-1 AP-ROP for disease regression and gaining time for development of macular vascularization.
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Cost-consequence analysis of extended loading dose from 3 to 6 months of anti-vegf treatment in diabetic macular edema patients () - Sep 26, 2019 - Abstract #EURETINA2019EURETINA_1187;
The extension of anti-VEGF loading dose from 3 to 6 injections would mean that it would be necessary to invest €5,882.77 (7.93 injections), €10,091.03 (13.60 injections) and €10,198.59 (29.85 injections) per additional patient (non-responder at month 3 and responder at month 6) responding to aflibercept, ranibizumab and bevacizumab, respectively. For the total of patients treated, on average €7,927.02 (13.70 injections) per additional responder patient would be needed.
- Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Comparison of a pro re nata treatment regimen with ranibizumab and a treat & extend treatment regimen with aflibercept in patients with retinal vein occlusions () - Sep 26, 2019 - Abstract #EURETINA2019EURETINA_1185;
EDTRS letter gain was less stable in the PRN-RAN group with a noticeable drop at month 6, whereas letter gain in the T&E-AFL group remained stable but did not improve after month 3. However, the mean number of injections was more than twice as high in the T&E group when compared to the PRN group.
- Lucentis (ranibizumab) / Roche, Novartis, Medidur (fluocinolone acetonide) / EyePoint Pharma
Long time real-life results following treatment with dexamethasone or fluocinolone acetonide intravitreal implant in patients with diabetic macular edema () - Sep 26, 2019 - Abstract #EURETINA2019EURETINA_1184;
In patients with recurrent DME the switch from anti-VEGF to steroids seems to be a good treatment option. We observed a comparable BCVA gain after DEX and FAc implants with the mean duration of effect for the FAc implant, i.e. without the need for supplemental therapies, being 23.1±13.2 months.